This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
ILD and respiratory illness in diseases classified elsewhere
ILD_ELSEWHERE
interstitial lung disease: A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of pulmonary alveoli that extends to the interstitium and beyond leading to diffuse pulmonary fibrosis. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditions
|
501 |
3. Check pre-conditions, main-only, mode, registry filtersNone 0 out of 7 registries used, show all original rules. |
0 |
4. Check minimum number of eventsNone |
0 |
5. Include endpoints |
188 |
6. Filter based on genotype QC (FinnGen only) |
184 |
Control definitions (FinnGen only)
- Control exclude
- ILD_ENDPOINTS
- Control conditions
- not RESP_ILL_DIS_CLASS_ELSEWHERE
Extra metadata
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
ILD and respiratory illness in diseases classified elsewhere
based on the number of shared cases.
Similar with more cases:
- Respiratory disorders in diseases classified elsewhere
- Interstitial lung disease
- Interstitial lung disease endpoints
- Other interstitial pulmonary diseases
- Respiratory diseases principally affecting the interstitium, IBD co-morbidites
Similar with less cases:
Case counts by codes
↥FinnGen case counts by registry codes:
No data for upset plot.
No data for upset table.
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 759 | 447 | 310 |
| Only index persons | 620 | 367 | 253 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 66.31 | 66.49 | 66.17 |
| Only index persons | 66.16 | 66.01 | 66.39 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 184 | 106 | 78 |
| Unadjusted period prevalence (%) | 0.04 | 0.04 | 0.04 |
| Median age at first event (years) | 64.98 | 64.03 | 66.29 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 188
- Matched controls
- 1880
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
53.8
171.5
148
121
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
56.6
163.5
106
42
L04AX01
ATC
azathioprine; systemic
62.5
153.2
93
29
P01BA02
ATC
hydroxychloroquine; oral
28.3
124.5
113
95
J84.9
ICD-10 Finland
Interstitial pulmonary disease, unspecified
+∞
120.0
102
*
J84.1
ICD-10 Finland
Other interstitial pulmonary diseases with fibrosis
2184.9
118.0
102
*
TGC00
NOMESCO Finland
Bronchial lavation
41.6
96.0
62
22
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
22.2
91.3
81
62
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
35.4
87.0
59
24
UGC12
NOMESCO Finland
Flexible bronchoscopy
18.4
83.9
84
79
J84.8
ICD-10 Finland
Other specified interstitial pulmonary diseases
+∞
81.3
72
*
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
20.1
78.8
71
55
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
38.0
68.0
44
15
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
12.9
66.8
86
115
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
15.4
59.8
61
57
J99.0*M05.1
ICD-10 Finland
Rheumatoid lung disease
+∞
59.6
54
*
L04AX03
ATC
methotrexate; systemic
12.1
59.1
76
100
L04AA06
ATC
mycophenolic acid; systemic
99.3
57.3
61
9
GD1AD
NOMESCO Finland
Thorax CT examination
16.1
56.7
55
47
L01BA01
ATC
methotrexate; systemic
22.0
54.0
43
25
XG410
NOMESCO Finland
Flow-volume spirometry
18.8
52.0
45
31
H02AB06
ATC
prednisolone; systemic
30.5
51.7
178
693
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
11.8
48.8
59
70
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
10.2
47.6
148
500
A07EC01
ATC
sulfasalazine; oral, rectal
11.1
47.2
60
76
J18.9
ICD-10 Finland
Pneumonia, unspecified
8.1
46.8
115
306
M06.9
ICD-10 Finland
Rheumatoid arthritis, unspecified
16.2
40.3
37
28
L88
ICPC
Rheumatoid/seropositive arthritis
16.3
38.4
35
26
M05.9
ICD-10 Finland
Seropositive rheumatoid arthritis, unspecified
18.0
38.3
33
22
J99.1
ICD-10 Finland
Respiratory disorders in other diffuse connective tissue disorders
+∞
37.8
35
*
J99.1*M35.0
ICD-10 Finland
Respiratory disorders in sicca syndrome [Sjögren]
+∞
34.4
32
*
J99.0
ICD-10 Finland
Rheumatoid lung disease
+∞
34.4
32
*
M05BA04
ATC
alendronic acid; oral
7.4
30.3
53
95
GD1AA
NOMESCO Finland
Thorax X-ray examination
6.5
29.5
146
654
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
9.4
27.4
36
46
M35.9
ICD-10 Finland
Systemic involvement of connective tissue, unspecified
47.7
26.8
32
8
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
7.1
25.7
45
80
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
4.8
25.3
94
325
ZX120
NOMESCO Finland
Intravenous
6.1
24.7
52
111
J99.1*M31.3
ICD-10 Finland
Respiratory disorders in Wegener's granulomatosis
+∞
24.5
23
*
R06.0
ICD-10 Finland
Dyspnoea
4.6
24.0
98
361
L04AA13
ATC
[U] leflunomide
23.2
23.1
33
17
J01MA14
ATC
moxifloxacin; systemic
5.9
22.5
48
103
M05.1
ICD-10 Finland
Rheumatoid lung disease
+∞
22.3
21
*
R50.9
ICD-10 Finland
Fever, unspecified
5.1
22.2
59
154
J99.1*M33.2
ICD-10 Finland
Respiratory disorders in polymyositis
+∞
21.2
20
*
M33.2
ICD-10 Finland
Polymyositis
235.0
21.0
21
*
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
6.2
17.6
33
62
J99.1*M34.8
ICD-10 Finland
Respiratory disorders in systemic: sclerosis
+∞
16.9
16
*
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
5.4
16.7
37
81
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
7.4
16.7
26
40
TPH04
NOMESCO Finland
Cathetrisation of vein
3.7
16.1
72
270
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
4.8
15.8
41
103
J01MA12
ATC
levofloxacin; systemic
3.8
15.6
64
226
J96.1
ICD-10 Finland
Chronic respiratory failure
22.4
15.5
22
11
M31.3
ICD-10 Finland
Wegener granulomatosis
49.5
15.4
18
*
R03AK08
ATC
formoterol and beclometasone; inhalant
7.3
14.8
23
35
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
4.6
14.8
41
108
M33.9
ICD-10 Finland
Dermatopolymyositis, unspecified
+∞
14.8
14
*
C03CA01
ATC
furosemide; systemic
3.3
14.7
89
399
XG470
NOMESCO Finland
Measurement of diffusion capastity of the lungs
14.4
13.8
23
18
M34.9
ICD-10 Finland
Systemic sclerosis, unspecified
81.2
13.8
15
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
4.3
13.5
40
111
TND11
NOMESCO Finland
Injection of diagnostic or therapeutic substance in joint, wrist or hand
30.9
13.2
17
6
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
13.7
13.0
22
18
L04AD01
ATC
ciclosporin; systemic
21.9
12.7
18
9
TFC00
NOMESCO Finland
Catheterisation of right atrium or ventricle
26.5
12.7
17
7
J99.1*M32.1
ICD-10 Finland
Respiratory disorders in systemic: lupus erythematosus
+∞
12.6
12
*
M33.1
ICD-10 Finland
Other dermatomyositis
138.9
12.6
13
*
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
13.7
12.5
21
17
M05BX04
ATC
denosumab; parenteral
5.0
12.4
29
66
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.5
12.3
54
196
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.8
12.1
43
135
NH3EA
NOMESCO Finland
Feet X-ray examination with load
16.1
12.1
19
13
XQ858
NOMESCO Finland
Oxygen partial pressure measurement
32.4
11.8
15
5
TGD04
NOMESCO Finland
Needle biopsy of the lungs in bronchoscopy
69.4
11.8
13
*
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
3.2
11.6
58
227
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
3.2
11.6
60
240
M34.0
ICD-10 Finland
Progressive systemic sclerosis
+∞
11.6
11
*
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
9.2
11.2
23
28
ND2BA
NOMESCO Finland
Hand and fingers extensive X-ray examination
13.1
11.1
19
16
M80.4
ICD-10 Finland
Drug-induced osteoporosis with pathological fracture
30.0
10.9
14
5
H02AB07
ATC
prednisone; oral
3.5
10.8
44
151
WZC30
NOMESCO Finland
Teaching
3.2
10.7
54
212
GX1K5
NOMESCO Finland
Diffusion capacity
116.2
10.5
11
*
M32.9
ICD-10 Finland
Systemic lupus erythematosus, unspecified
25.0
10.4
14
6
L04AA01
ATC
[U] ciclosporin
25.0
10.4
14
6
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.2
10.3
51
197
SPAT1229
SPAT
Assessment of need for aid
4.3
10.2
29
77
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.8
10.2
79
391
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
2.7
10.1
107
619
U07.1
ICD-10 Finland
Emergency use of U07.1 | COVID-19, virus identified
3.3
9.9
45
165
M13.9
ICD-10 Finland
Arthritis, unspecified
4.2
9.9
29
79
SPAT1255
SPAT
Intravenous administration of medicine
4.6
9.8
25
61
K21.9
ICD-10 Finland
Gastro-oesophageal reflux disease without oesophagitis
3.8
9.7
33
100
H04.10
ICD-10 Finland
Dry eye syndrome
3.5
9.6
38
128
M01CB01
ATC
sodium aurothiomalate; parenteral
31.8
9.5
12
*
GCA98
NOMESCO Finland
Other bronchoscopic procedure on bronchus
31.8
9.5
12
*
TNB11
NOMESCO Finland
Injection of diagnostic or therapeutic substance in shoulder joint
+∞
9.4
9
*
J99.1*M33.9
ICD-10 Finland
Respiratory disorders in dermatopolymyositis
+∞
9.4
9
*
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
4.4
9.2
25
64
R03BA08
ATC
ciclesonide; inhalant
3.6
8.8
32
101
R81
ICPC
Pneumonia
7.6
8.8
20
29
R03AC02
ATC
salbutamol; inhalant
2.6
8.7
125
814
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
3.4
8.7
36
124
R28
ICPC
Limited function/disability (R)
17.3
8.7
13
8
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
3.8
8.5
28
83
M34.8
ICD-10 Finland
Other forms of systemic sclerosis
+∞
8.4
8
*
J01AA02
ATC
doxycycline; systemic
3.5
8.4
164
1240
Z01.8
ICD-10 Finland
Other specified special examinations
2.7
8.3
56
254
GDA11
NOMESCO Finland
Thoracoscopic biopsy of lung
35.0
8.2
10
*
SPAT1083
SPAT
Initiation and monitoring of IV fluid therapy
7.2
8.1
19
29
NF1AE
NOMESCO Finland
Hip joint ultrasound examination
11.5
7.9
14
13
B01AA03
ATC
warfarin; systemic
2.7
7.9
50
219
L30.9
ICD-10 Finland
Dermatitis, unspecified
2.7
7.8
49
214
NH3DA
NOMESCO Finland
Bilateral foot X-ray examination
12.6
7.7
13
11
NA1EA
NOMESCO Finland
Cervical spine X-ray examination with flexion
19.4
7.7
11
6
M34.1
ICD-10 Finland
CR(E)ST syndrome
26.2
7.7
10
*
M35.1
ICD-10 Finland
Other overlap syndromes
83.2
7.5
8
*
I27.2
ICD-10 Finland
Other secondary pulmonary hypertension
83.2
7.5
8
*
Z94.2
ICD-10 Finland
Lung transplant status
83.2
7.5
8
*
GX1D5
NOMESCO Finland
Flow volume spirometry
83.2
7.5
8
*
NG1DA
NOMESCO Finland
X-ray of knees
11.5
7.4
13
12
WX726
NOMESCO Finland
High-flow oxygen therapy
+∞
7.3
7
*
GD1BT
NOMESCO Finland
Biopsy of lung with X-ray guidance
+∞
7.3
7
*
XF614
NOMESCO Finland
Measurement of pulmonary artery pressure
+∞
7.3
7
*
M31.1
ICD-10 Finland
Thrombotic microangiopathy
+∞
7.3
7
*
M31.8
ICD-10 Finland
Other specified necrotizing vasculopathies
+∞
7.3
7
*
M32.1
ICD-10 Finland
Systemic lupus erythematosus with organ or system involvement
+∞
7.3
7
*
A02BC02
ATC
pantoprazole; systemic
2.6
7.3
145
1058
ZX108
NOMESCO Finland
Inhalation
31.3
7.2
9
*
L01AA01
ATC
cyclophosphamide; systemic
31.3
7.2
9
*
M81.4
ICD-10 Finland
Drug-induced osteoporosis
31.3
7.2
9
*
J12.8
ICD-10 Finland
Other viral pneumonia
21.0
7.2
10
5
GD1CD
NOMESCO Finland
Thorax extensive CT-examination
21.0
7.2
10
5
NH3BA
NOMESCO Finland
Foot and toes extensive X-ray examination
6.8
7.1
17
27
L04AB01
ATC
etanercept; parenteral
14.5
7.0
11
8
ND2DA
NOMESCO Finland
Bilateral hand X-ray examination
11.6
6.9
12
11
XCW99
NOMESCO Finland
Other investigative procedure of eye
3.1
6.9
31
112
SPAT1249
SPAT
Treatment-related counselling outside office
2.3
6.8
87
520
J01FF01
ATC
clindamycin; systemic
2.4
6.8
65
344
R60.9
ICD-10 Finland
Oedema, unspecified
4.3
6.8
18
45
J01FA06
ATC
roxithromycin; oral
2.2
6.8
93
573
M10.9
ICD-10 Finland
Gout, unspecified
3.7
6.5
21
61
TNH11
NOMESCO Finland
Injection of diagnostic or therapeutic substance in ankle joint or foot joint
15.0
6.5
10
7
M35.8
ICD-10 Finland
Other specified systemic involvement of connective tissue
72.2
6.5
7
*
M32.8
ICD-10 Finland
Other forms of systemic lupus erythematosus
72.2
6.5
7
*
J17.3*B59
ICD-10 Finland
Pneumonia due to Pneumocystis carinii
72.2
6.5
7
*
GX2C5
NOMESCO Finland
Short-lasting oximetry
72.2
6.5
7
*
XF622
NOMESCO Finland
Measurement of minute volume of heart
72.2
6.5
7
*
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
3.1
6.4
29
105
WW200
NOMESCO Finland
Immunization
9.8
6.4
12
13
N08.5*M31.3
ICD-10 Finland
Glomerular disorders in Wegener's granulomatosis
+∞
6.3
6
*
J84.0
ICD-10 Finland
Alveolar and parietoalveolar conditions
+∞
6.3
6
*
L01EX09
ATC
nintedanib; oral
+∞
6.3
6
*
C02KX04
ATC
macitentan; oral
+∞
6.3
6
*
GDG10
NOMESCO Finland
Bilateral transplantation of lung
+∞
6.3
6
*
356
Kela drug reimbursment
Nintedanib and pirfenidone
+∞
6.3
6
*
A01AB09
ATC
miconazole; local oral
3.2
6.2
27
95
ZY020
NOMESCO Finland
Telephone, letter or other consultation without direct patient contact
3.3
6.2
24
79
7140A
ICD-9 Finland
Rheumatoid arthritis and other inflammatory polyarthropathies, Rheumatoid arthritis[ARTHRITIS RHEUMATOIDES SEROPOSITIVA]
13.1
6.2
10
8
M05BA07
ATC
risedronic acid; oral
6.4
6.1
15
25
XG466
NOMESCO Finland
Sleep oxymetry
6.4
6.1
15
25
C08CA05
ATC
nifedipine; systemic
3.4
6.1
23
74
I50.9
ICD-10 Finland
Heart failure, unspecified
2.7
6.1
37
157
J01CA04
ATC
amoxicillin; systemic
2.8
6.1
161
1277
A02BC01
ATC
omeprazole; systemic
2.2
6.1
65
358
H02AB04
ATC
methylprednisolone; systemic
2.7
6.1
38
164
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
72
50
22.72
84.91
3.4
1.5
—
—
—
0
0
61
39
22.67
74.33
1.7
1.3
9.73
1.62
u/ml
—
27
5
44
11
51.92
74.11
2.4
1.5
—
—
—
0
0
55
30
25.50
71.88
1.5
1.2
23.44
—
u/ml
—
11
0
56
34
23.03
69.69
1.5
1.2
47.17
—
u/ml
—
7
0
63
50
18.45
68.43
3.6
2.4
—
—
—
0
0
63
54
17.04
65.36
2.8
1.2
1.21
1.19
g/l
0.11
63
54
44
29
19.50
51.99
2.3
1.7
—
—
—
0
0
37
18
25.35
49.97
1.5
1.3
42.40
—
u/ml
—
7
0
40
24
20.90
49.33
2.4
1.7
—
—
—
0
0
50
49
13.54
46.98
1.8
1.6
0.98
0.09
iu/ml
0.76
17
11
44
39
14.42
43.88
2.7
1.6
—
—
—
0
0
45
42
13.77
43.46
2.9
1.6
—
—
—
0
0
98
239
7.48
42.88
3.1
1.9
—
—
—
0
0
42
37
14.33
41.96
2.2
1.3
—
—
—
0
0
36
29
15.12
37.76
2.8
1.6
—
—
—
0
0
44
53
10.53
35.38
3.6
1.9
96.67
192.00
titre
—
6
5
33
26
15.18
34.95
2.1
1.7
—
—
—
0
0
94
262
6.18
34.52
1.5
1.3
105.11
40.45
iu/ml
1.33
53
88
75
173
6.55
33.68
2.5
1.8
—
—
—
0
0
75
176
6.43
33.01
2.7
1.9
—
—
—
0
0
33
29
13.59
32.71
17.5
7.0
166.80
158.83
iu/ml
—
5
6
157
711
8.33
32.59
23.3
5.7
65.12
57.03
%
12.62
157
674
157
719
8.18
31.92
25.0
5.9
20.96
27.93
%
14.77
157
679
88
253
5.66
30.62
1.5
1.3
60.45
13.97
u/ml
1.89
35
94
32
33
11.48
28.48
2.4
1.5
394.29
—
titre
—
7
0
29
28
12.06
26.91
2.5
1.7
—
—
—
0
0
29
28
12.06
26.91
2.5
1.7
—
—
—
0
0
118
472
5.03
26.55
7.3
2.0
100.55
219.36
u/l
2.25
113
447
27
28
11.09
23.80
5.4
4.5
61.78
59.68
%
0.26
27
28
179
1174
11.95
23.67
22.4
4.2
21.65
11.94
mm/h
9.24
179
1066
43
80
6.67
23.38
7.7
3.0
2.27
2.17
mmol/l
0.06
34
59
65
186
4.81
21.79
9.7
7.4
1.72
1.21
mmol/l
0.41
52
156
147
775
5.11
21.29
10.4
6.6
1.21
1.22
mmol/l
1.53
130
650
129
629
4.35
20.51
3.5
2.2
81.19
77.53
nmol/l
0.82
123
547
32
22
17.27
20.28
2.1
1.8
—
—
—
0
0
29
41
8.18
20.11
2.0
1.5
—
—
—
0
0
135
703
4.26
18.99
10.3
5.7
1.20
1.22
mmol/l
2.93
130
639
30
21
16.75
18.87
1.3
1.1
—
—
—
0
0
27
39
7.92
18.34
1.8
1.2
—
—
—
0
0
141
778
4.25
17.74
10.9
5.1
0.00
0.00
estimate
-0.00
47
161
142
789
4.27
17.64
8.7
3.9
0.00
0.00
estimate
-0.00
48
155
140
774
4.17
17.43
8.7
3.8
0.00
0.01
estimate
0.50
49
175
123
630
3.75
17.07
6.1
3.9
51.46
34.20
ng/l
0.54
109
458
28
23
14.09
16.49
3.4
1.4
—
—
—
0
0
37
84
5.24
16.02
1.5
1.3
262.24
186.07
u/ml
0.29
29
79
43
113
4.64
15.63
12.3
6.3
8.70
9.49
mmol/l
0.46
43
105
19
6
34.96
15.12
1.8
1.3
—
—
—
0
0
24
19
14.29
14.36
3.4
1.3
—
—
—
0
0
17
5
37.12
13.76
1.3
1.0
—
—
—
0
0
26
28
10.59
13.49
5.3
3.8
4.54
4.93
e9/l
0.25
26
28
20
12
18.47
13.31
3.4
2.4
—
—
—
0
0
176
1255
7.30
13.27
23.9
7.2
70.74
78.42
u/l
2.66
176
1165
91
439
3.08
12.91
10.0
4.0
0.00
0.00
estimate
-0.00
48
157
126
758
3.01
11.53
23.8
12.6
1.29
1.25
inr
0.20
48
226
104
577
2.80
10.89
9.2
2.9
—
—
—
0
0
18
15
13.13
10.60
1.7
2.0
—
—
—
0
0
18
15
13.13
10.60
2.1
2.1
—
—
—
0
0
18
15
13.13
10.60
1.7
2.0
—
—
—
0
0
18
15
13.13
10.60
1.7
2.0
—
—
—
0
0
54
217
3.09
10.22
3.4
2.3
16.00
22.37
%
3.89
49
186
18
17
11.57
10.03
2.8
1.7
—
—
—
0
0
18
17
11.57
10.03
2.1
2.0
—
—
—
0
0
18
17
11.57
10.03
2.8
1.7
—
—
—
0
0
22
48
5.06
9.82
3.0
2.1
—
—
—
0
0
71
338
2.77
9.80
2.2
1.7
1.47
1.36
mg/l
0.09
59
271
15
10
16.16
9.69
3.1
1.3
—
—
—
0
0
15
10
16.16
9.69
3.1
1.3
—
—
—
0
0
105
611
2.63
9.63
10.0
3.9
—
—
—
0
0
16
14
12.37
9.26
3.4
1.3
—
—
—
0
0
22
51
4.75
9.14
1.2
4.3
50.71
49.51
mg/l
0.03
16
38
22
51
4.75
9.14
1.2
4.3
71.98
27.36
mg/l
0.65
16
38
15
12
13.46
9.04
3.1
1.4
—
—
—
0
0
50
205
2.96
9.04
14.0
7.3
104.04
103.95
mmol/l
0.04
50
205
20
29
7.58
8.82
4.2
2.3
14.75
16.54
%
1.09
11
14
28
83
3.79
8.46
2.0
1.9
—
—
—
0
0
83
453
2.49
8.43
7.4
2.8
0.41
0.41
e6/l
0.01
76
329
38
139
3.17
8.32
3.6
3.6
3.09
2.12
mmol/l
0.88
33
113
11
5
23.22
8.11
1.5
1.0
7.37
11.25
ug/l
—
11
5
33
114
3.30
7.91
1.8
1.5
—
—
—
0
0
23
62
4.09
7.90
1.5
2.4
—
—
—
0
0
19
45
4.58
7.67
2.6
1.9
—
—
—
0
0
28
91
3.44
7.37
20.1
6.8
26.28
25.03
mmol/l
0.81
28
91
19
34
6.09
7.29
3.8
1.9
122.00
128.88
g/l
0.47
12
24
10
5
21.00
7.21
3.0
1.6
62.55
63.80
ug/l
—
10
5
35
133
3.00
7.14
4.6
2.5
58.44
61.72
ml/min/173m2
0.24
18
53
16
24
7.18
6.98
1.2
1.2
1.67
1.25
u/ml
—
6
8
12
11
11.55
6.90
1.8
1.7
—
—
—
0
0
12
11
11.55
6.90
1.7
1.7
—
—
—
0
0
18
33
5.92
6.81
11.9
2.9
5.13
5.04
kpa
0.17
18
33
14
18
8.31
6.75
1.4
1.2
—
—
—
0
0
14
18
8.31
6.75
1.4
1.2
—
—
—
0
0
12
12
10.59
6.64
1.0
1.2
—
—
—
0
0
14
19
7.86
6.54
1.4
1.2
—
—
—
0
0
14
19
7.86
6.54
1.4
1.2
—
—
—
0
0
14
19
7.86
6.54
1.4
1.2
—
—
—
0
0
13
16
8.64
6.45
2.5
2.2
87.12
88.91
%
0.47
13
16
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
18
47
4.13
6.43
7.6
2.1
0.36
0.37
u/ml
—
10
24
12
14
9.07
6.15
1.3
1.1
—
—
—
0
0
13
19
7.26
5.84
2.7
4.1
—
—
—
0
0
15
27
5.94
5.82
1.2
1.1
1.71
5.23
u/ml
—
7
13
61
334
2.22
5.77
1.3
1.2
0.69
1.50
u/ml
0.75
22
95
11
13
8.91
5.64
1.2
1.2
—
—
—
0
0
9
8
11.73
5.35
1.4
1.9
—
—
—
0
0
9
8
11.73
5.35
1.4
1.9
—
—
—
0
0
9
8
11.73
5.35
1.4
1.9
—
—
—
0
0
10
12
8.73
5.13
1.6
1.5
—
—
—
0
0
10
13
8.05
4.91
1.4
1.1
—
—
—
0
0
15
43
3.70
4.72
1.5
2.0
—
—
—
0
0
23
87
2.87
4.69
1.6
1.2
—
—
—
0
0
17
54
3.36
4.61
1.4
1.1
—
—
—
0
0
15
44
3.62
4.57
1.3
1.3
—
—
—
0
0
36
173
2.34
4.55
5.2
3.1
—
—
—
0
0
114
835
1.93
4.53
3.3
2.7
—
—
—
0
0
31
140
2.45
4.48
3.1
2.4
9.08
9.17
ug/l
0.01
26
128
148
1190
2.15
4.46
4.6
4.0
15.39
14.94
pmol/l
1.13
143
1060
21
78
2.91
4.42
4.0
2.6
1.67
1.19
%
1.01
21
78
11
20
5.77
4.36
1.2
1.3
—
—
—
0
0
60
361
1.97
4.26
1.8
1.8
499.60
455.27
pmol/l
0.49
55
299
13
30
4.58
4.22
1.5
1.6
—
—
—
0
0
49
277
2.04
4.12
4.3
2.4
0.54
1.11
e6/l
1.81
39
149
20
76
2.83
4.05
3.6
2.6
0.71
0.63
%
0.37
20
76
14
37
4.00
3.99
1.1
1.1
—
—
—
0
0
16
54
3.15
3.95
1.4
1.1
—
—
—
0
0
7
9
8.02
3.59
3.9
7.4
—
—
—
0
0
9
17
5.50
3.55
1.8
1.4
—
—
—
0
0
12
32
3.93
3.46
1.4
1.2
—
—
—
0
0
12
32
3.93
3.46
1.4
1.2
—
—
—
0
0
9
18
5.19
3.41
1.0
1.8
—
—
—
0
0
9
18
5.19
3.41
1.0
1.8
—
—
—
0
0
9
18
5.19
3.41
1.0
1.8
—
—
—
0
0
9
18
5.19
3.41
1.0
1.8
—
—
—
0
0
9
18
5.19
3.41
1.0
1.8
—
—
—
0
0
159
1361
2.09
3.37
46.3
17.4
16.37
15.11
%
1.63
159
1342
9
19
4.92
3.28
1.0
1.8
—
—
—
0
0
53
333
1.82
3.20
12.5
4.1
1.02
1.02
kg/l
—
6
45
99
744
1.70
3.18
3.8
2.5
—
—
—
0
0
12
35
3.59
3.17
1.0
1.6
—
—
—
0
0
8
16
5.17
3.08
1.1
1.2
—
—
—
0
0
5
5
10.22
2.99
1.2
2.0
—
—
—
0
0
5
5
10.22
2.99
1.2
2.0
—
—
—
0
0
5
5
10.22
2.99
1.6
1.6
—
—
—
0
0
8
17
4.86
2.95
2.1
1.9
—
—
—
0
0
180
1664
2.92
2.90
49.4
17.1
80.42
77.43
umol/l
0.76
180
1664
6
9
6.84
2.89
1.0
1.3
—
—
—
0
0
47
294
1.80
2.85
2.4
2.7
2.46
2.46
mmol/l
0.01
41
257
9
23
4.06
2.81
1.2
1.1
—
—
—
0
0
18
79
2.41
2.77
1.4
1.2
—
—
—
0
0
5
6
8.52
2.76
1.2
2.0
—
—
—
0
0
5
6
8.52
2.76
1.2
2.0
—
—
—
0
0
12
44
2.85
2.60
1.6
1.4
344.00
271.58
ug/g
—
7
24
180
1676
2.74
2.47
33.8
10.5
25.12
24.95
u/l
0.04
180
1609
5
8
6.38
2.38
1.4
1.1
13.00
14.50
u/l
—
5
8
9
29
3.21
2.26
1.1
1.1
—
—
—
0
0
11
42
2.72
2.18
1.0
1.1
—
—
—
0
0
20
103
2.05
2.15
1.3
1.3
—
27.79
—
0
7
10
37
2.80
2.10
1.1
1.3
—
—
—
0
0
176
1627
2.28
2.10
42.3
16.6
139.19
139.77
mmol/l
2.18
176
1579
176
1632
2.23
1.99
42.4
16.7
3.96
3.98
mmol/l
0.60
176
1584
160
1440
1.75
1.99
5.5
4.8
1.97
1.95
mu/l
0.08
154
1293
81
634
1.49
1.90
2.0
1.9
97.23
96.06
pmol/l
0.09
54
296
5
13
3.92
1.72
1.0
1.0
—
—
—
0
0
50
363
1.51
1.65
3.2
2.2
—
—
—
0
0
10
43
2.40
1.61
4.5
2.0
1.76
1.69
mg/l
—
10
36
35
246
1.52
1.34
3.0
1.9
30.65
29.26
s
0.99
35
238
8
35
2.34
1.28
1.6
1.4
—
—
—
0
0
117
1027
1.37
1.26
5.2
2.9
80.62
48.26
u/l
0.53
111
953
180
1728
1.98
1.20
63.8
21.1
4.36
4.49
e12/l
2.86
180
1682
180
1728
1.98
1.20
64.2
21.2
129.36
135.49
g/l
7.21
180
1700
180
1727
1.99
1.20
64.0
21.3
39.94
40.05
%
0.12
171
1607
180
1726
2.01
1.20
63.6
21.2
263.74
247.06
e9/l
2.63
180
1688
5
22
2.31
1.04
1.0
1.1
—
—
—
0
0
55
443
1.34
1.01
1.7
1.7
1.55
1.31
mmol/l
1.87
47
369
33
255
1.36
0.79
6.3
2.6
2.15
2.85
e6/l
0.23
23
130
158
1498
1.34
0.74
36.5
13.8
77.87
78.73
ml/min/173m2
0.19
149
1227
61
529
1.23
0.61
6.2
3.8
8.59
7.89
mg/mmol
0.08
48
317
7
112
0.61
0.60
2.4
1.7
—
—
—
0
0
6
36
1.69
0.57
1.0
1.3
—
220.88
—
0
11
28
224
1.29
0.55
1.4
1.4
—
—
—
0
0
0
16
0.00
0.41
0.0
1.0
—
1.00
—
0
5
6
41
1.48
0.36
1.5
1.3
—
—
—
0
0
7
52
1.36
0.31
1.0
1.3
—
—
—
0
0
26
301
0.84
0.30
3.0
3.1
0.64
0.76
ug/l
0.54
17
197
151
1549
0.87
0.27
5.2
4.7
5.74
6.02
mmol/l
3.01
141
1406
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
177.35
—
0
10
0
12
0.00
0.21
0.0
1.6
—
—
—
0
0
0
12
0.00
0.21
0.0
1.6
—
—
—
0
0
0
12
0.00
0.21
0.0
1.6
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
41.88
—
0
8
0
13
0.00
0.21
0.0
1.0
—
451.75
—
0
8
0
14
0.00
0.20
0.0
2.0
—
—
—
0
0
12
99
1.23
0.20
1.0
1.9
—
—
—
0
0
8
71
1.13
0.16
1.4
1.0
—
—
—
0
0
148
1505
0.92
0.13
4.5
4.2
1.43
1.27
mmol/l
2.49
141
1363
13
148
0.87
0.13
1.6
2.6
37.08
34.23
u/l
0.19
13
121
21
194
1.09
0.09
10.7
7.9
—
—
—
0
0
154
1554
0.95
0.06
4.9
4.7
1.43
1.50
mmol/l
1.16
143
1417
161
1599
1.05
0.04
5.3
5.3
2.56
2.74
mmol/l
1.82
148
1457
51
498
1.03
0.04
3.7
5.2
1.69
2.86
ug/l
1.03
45
438
39
399
0.97
0.02
3.6
4.7
23.72
21.81
%
0.36
22
199
21
211
0.99
0.00
1.6
1.4
—
—
—
0
0
156
1561
1.00
0.00
4.9
4.7
4.45
4.68
mmol/l
2.00
144
1435
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
9
89
1.01
-0.00
1.0
1.9
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
0.31
—
0
6
0
5
0.00
-0.00
0.0
1.2
—
5.86
—
0
5
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
4.8
—
60.30
—
0
5
Mortality – FinRegistry
↥Association
Association between endpoint ILD_ELSEWHERE and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| ILD_ELSEWHERE | 3.489 [2.71, 4.5] | < 0.001 |
| Birth year | 0.996 [0.99, 1.0] | 0.353 |
During the follow-up period (1.1.1998 — 31.12.2019), 146 out of 355 females with ILD_ELSEWHERE died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| ILD_ELSEWHERE | 3.206 [2.23, 4.61] | < 0.001 |
| Birth year | 0.987 [0.98, 1.0] | 0.009 |
During the follow-up period (1.1.1998 — 31.12.2019), 110 out of 242 males with ILD_ELSEWHERE died.
Mortality risk
Mortality risk for people of age
years, who have ILD_ELSEWHERE.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.286% | 0.576% |
| 5 | 2.039% | 3.501% |
| 10 | 5.545% | 8.929% |
| 15 | 10.315% | 17.278% |
| 20 | 17.819% | 28.56% |
Relationships between endpoints
↥Index endpoint: ILD_ELSEWHERE – ILD and respiratory illness in diseases classified elsewhere
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data